Table 3.
Relative risk for overall survival of 22,458 patients.
| Unadjusted RR (95% CI) | P-value | Adjusted RR (95% CI) | P-value | |
|---|---|---|---|---|
| Age | ||||
| <30 vs. 40–49 | 0.921 (0.904–0.939) | <0.0001 | 0.890 (0.907–0.875) | <0.0001 |
| <30 vs. 50–59 | 0.837 (0.816–0.861) | <0.0001 | 0.827 (0.806–0.849) | <0.0001 |
| <30 vs. 60–69 | 0.812 (0.774–0.853) | <0.0001 | 0.821 (0.784–0.861) | <0.0001 |
| <30 vs. ≥70 | 0.773 (0.695–858) | <0.0001 | 0.779 (0.702–0.864) | <0.0001 |
| Sex (female vs. male) | 0.802 (0.787–0.818) | <0.0001 | 0.907 (0.888–0.925) | <0.0001 |
| Anticoagulation (non-user vs. user) | 1.072 (1.009–1.139) | 0.024 | 0.957 (0.983–1.044) | 0.159 |
| COPD (absence vs. presence) | 0.888 (0.858–0.918) | <0.0001 | 0.988 (0.955–1.779) | 0.465 |
| Brain metastasis (presence vs. absence) | 1.089 (1.125–1.053) | <0.0001 | 1.250 (1.208–1.294) | <0.0001 |
| First-line systemic treatment (TT vs. CC) | 0.669 (0.653–0.686) | <0.0001 | 0.686 (0.668–0.704) | <0.0001 |
Abbreviations: RR, relative risk; CI, confidence interval; CC, cytotoxic chemotherapy; TT, targeted therapy; COPD, chronic obstructive pulmonary disease.